Weekly low-dose rapamycin is perhaps the most discussed and least formally studied longevity intervention among the biohacker community. Here is what the emerging observational data actually shows.
mTORC1 Inhibition Basics
Rapamycin inhibits mTORC1, the master regulator of cellular growth and metabolism. In animal models, it extends lifespan even when started in late life — the most compelling mechanistic argument for its human application.
The Self-Reported Cohort
158 individuals (Longevity Research Institute, 2025) self-reporting weekly rapamycin dosing (2–6mg once weekly) for 6–24 months. Key findings: no significant immunosuppression at these doses, lipid profiles modestly elevated, subjective energy improvement reported by 68%.
The Critical Caveat
This is self-reported observational data from a motivated, health-conscious cohort. Selection bias is extreme. No RCT exists. We are applying the CONTESTED flag to efficacy claims while maintaining OBS for safety signals.
